GLP-1 drugs like Ozempic have already become a game-changer for obesity and diabetes. But new research shows they may also ...

FAT jabs are better than widely prescribed metformin when it comes to curbing dementia risk in people with type 2 diabetes, ...

A new study suggests that drugs like Ozempic and Mounjaro may reduce dementia risk. Researchers at the University of Galway found a 45% lower risk in patients taking these medications. The drugs may ...

Case Western Reserve researchers found semaglutide users had significantly lower Alzheimer's-related dementia risk compared to those on other medications.

Semaglutide — the active ingredient in type 2 diabetes and weight-loss glucagon-like peptide-1 agonist ( GLP-1) medications Ozempic and Wegovy — may help lower dementia risk, a new study finds.

Diabetics are more likely to develop Alzheimer’s than the general public. Could a popular diabetes and weight-loss drug also stave off dementia?

Benefits were most prominent among women, patients older than 60 and those with a body mass index of 30 to 40.

Ozempic use is associated with a lowered risk for cognitive problems, researchers in a new study said. The findings, however, cannot be applied to users who do not have diabetes. The study ...

Diabetes and weight loss treatments such as Ozempic and Wegovy, known as GLP-1 agonists, could significantly reduce the risk of developing any type of dementia, according to a meta-analysis of 26 ...

Novo Nordisk A/S’s Ozempic was linked to lower rates of dementia and a range of other mental problems in a University of Oxford study that raises expectations about the diabetes drug’s ...

"These were not clinical trials specifically to look at dementia, but based on what they saw in those trials, there was a hint that these newer medications, like Ozempic, like Mounjaro, may reduce ...

Researchers analyzed 130,000 U.S. diabetes patients, including about 20,000 taking semaglutide, known by the brand name Ozempic for diabetes, or Wegovy for weight loss.